Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy.

Z. Salah*, T. Bar-mag, Y. Kohn, F. Pichiorri, T. Palumbo, G. Melino, R. I. Aqeilan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


The WWOX tumor suppressor is a WW domain-containing protein. Its function in the cell has been shown to be mediated, in part, by interacting with its partners through its first WW (WW1) domain. Here, we demonstrated that WWOX via WW1 domain interacts with p53 homolog, ΔNp63α. This protein-protein interaction stabilizes ΔNp63α, through antagonizing function of the E3 ubiquitin ligase ITCH, inhibits nuclear translocation of ΔNp63α into the nucleus and suppresses ΔNp63α transactivation function. Additionally, we found that this functional crosstalk reverses cancer cells resistance to cisplatin, mediated by ΔNp63α, and consequently renders these cells more sensitive to undergo apoptosis. These findings suggest a functional crosstalk between WWOX and ΔNp63α in tumorigenesis.

Original languageAmerican English
JournalUnknown Journal
StatePublished - 2013

Bibliographical note

Funding Information:
Acknowledgements. We are grateful to all members of the Aqeilan’s lab for their technical help and fruitful discussion. This work was supported, in part, by funds from Israel Science Foundation (ISF; #12-0542) to RIA and Israeli Cancer Research Funds (ICRF) to RIA and ZS.


Dive into the research topics of 'Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy.'. Together they form a unique fingerprint.

Cite this